Top

Published in:

20-01-2022 | Type 1 Diabetes | Original Article

Association of IGHM polymorphisms with susceptibility to type 1 diabetes

Authors: Zouidi Ferjeni, Fakhfakh Raouia, O. Abida, C. Penha-Gonçalves, H. Masmoudi

Published in: Immunologic Research | Issue 3/2022

Abstract

Differentiation of B lymphocytes is accompanied by a regulated switch in the expression pattern and stability of surface and secretory immunoglobulins (Igs). Several lines of evidence show that autoimmune responses evolving in much autoimmune pathologies were associated with a high level of humoral Ig, but their pathogenic role remains elusive. The aim of this study was to test the hypothesis that variants at the immunoglobulin heavy-chain IGH locus are genetic determinants to T1D susceptibility. Here, we tested the genetic association of the variants of the immunoglobulin heavy-chain IGH locus as a genetic determinant to T1D susceptibility. A total of 255 subjects from 59 Tunisian families were genotyped for 15 SNPs mapping in 4 regions in IGH locus. We found that rs1950942, rs2180790, rs1808152, and rs1956596 of IGHM and rs2516751 variant located in the IGHA1/IGHG2 region were significantly associated with a risk for T1D p = 7E-3; p = 0.03; p = 0.02; p = 0.043; and p = 3.65E-5, respectively. The TATGG haplotype derived from LD across three SNPs from IGHM gene and two SNPs from IGHD gene was significantly over-transmitted from parents to affect offspring. Our results suggest that genetic variants at the IGH locus are associated with T1D susceptibility. These variations may predispose to IgG AutoAbs production against pancreatic antigens and AutoAbs multi-reactivity, leading to T1D development.

Watson CT, Breden F. The immunoglobulin heavy chain locus: genetic variation, missing data, and implications for human disease. Genes Immun. 2012;13(5):363–73.CrossRef

Robinson WH. Sequencing the functional antibody repertoire—diagnostic and therapeutic discovery. Nat Rev Rheumatol. 2015;11(3):171.CrossRef

Lefranc M-P, Lefranc G. The immunoglobulin factsbook. Academic press; 2001.

Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class switch recombination. Annual review of immunology. 2008;26.

Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJ, Bingley PJ, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004;53(2):384–92.CrossRef

Hoppu S, Härkönen T, Ronkainen MS, Åkerblom HK, Knip M, Group CDiFS. IA-2 antibody epitopes and isotypes during the prediabetic process in siblings of children with type 1 diabetes. Journal of autoimmunity. 2004;23(4):361–70.CrossRef

Decraene T, Vandewalle C, Pipeleers D, Gorus F. Increased concentrations of total IgM at clinical onset of type 1 (insulin-dependent) diabetes: correlation with IgM binding to cells. The Belgian Diabetes Registry Clinical chemistry. 1992;38(9):1762–7.PubMed

Dean B, Becker F, McNally J, Tarn A, Schwartz G, Gale E, et al. Insulin autoantibodies in the pre-diabetic period: correlation with islet cell antibodies and development of diabetes. Diabetologia. 1986;29(5):339–42.CrossRef

Hawa MI, Fava D, Medici F, Deng Y-J, Notkins AL, De Mattia G, et al. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care. 2000;23(2):228–33.CrossRef

10.

Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7(6):812–8.CrossRef

11.

Merbl Y, Zucker-Toledano M, Quintana FJ, Cohen IR. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Investig. 2007;117(3):712–8.CrossRef

12.

Rolim I, Duarte N, Barata G, Costa J, Gardete-Correia L, Boavida J, et al. Immunoglobulin M gene association with autoantibody reactivity and type 1 diabetes. Immunogenetics. 2017;69(7):429–37.CrossRef

13.

Côrte-Real J, Duarte N, Tavares L, Penha-Gonçalves C. Innate stimulation of B1a cells enhances the autoreactive IgM repertoire in the NOD mouse: implications for type 1 diabetes. Diabetologia. 2012;55(6):1761–72.CrossRef

14.

Zouidi F, Stayoussef M, Bouzid D, Fourati H, Abida O, Ayed MB, et al. Contribution of PTPN22, CD28, CTLA-4 and ZAP-70 variants to the risk of type 1 diabetes in Tunisians. Gene. 2014;533(1):420–6.CrossRef

15.

Consortium WTCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661.CrossRef

16.

Hua RX, Fu W, Lin A, Zhou H, Cheng J, Zhang J et al. Role of FTO gene polymorphisms in Wilms tumor predisposition: A five‐center case–control study. The Journal of Gene Medicine. 2021:e3348.

17.

Ren H, Zhuo Z-J, Duan F, Li Y, Yang Z, Zhang J et al. ALKBH5 gene polymorphisms and hepatoblastoma susceptibility in chinese children. Journal of oncology. 2021;2021.

18.

Zhuo Z, Miao L, Hua W, Chen H, Yang Z, Li Y et al. Genetic variations in nucleotide excision repair pathway genes and hepatoblastoma susceptibility. International journal of cancer. 2021.

19.

Hakonarson H, Grant SF, Bradfield JP, Marchand L, Kim CE, Glessner JT, et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature. 2007;448(7153):591–4.CrossRef

20.

Cianci R, D’Addabbo P, Gambassi G, Lolli S, Serone E, Rizzi A, et al. Association between IgH enhancer hs1 2 and type 1 diabetes. Acta diabetologica. 2018;55(5):443–8.CrossRef

21.

Tolusso B, Frezza D, Mattioli C, Fedele AL, Bosello S, Faustini F, et al. Allele* 2 of the HS1, 2A enhancer of the Ig regulatory region associates with rheumatoid arthritis. Ann Rheum Dis. 2009;68(3):416–9.CrossRef

22.

Frezza D, Tolusso B, Giambra V, Gremese E, Marchini M, Nowik M, et al. Polymorphisms of the IgH enhancer HS1 2 and risk of systemic lupus erythematosus. Annals of the rheumatic diseases. 2012;71(8):1309–15.CrossRef

23.

Frezza D, Giambra V, Tolusso B, De Santis M, Bosello S, Vettori S, et al. Polymorphism of immunoglobulin enhancer element HS1, 2A: allele* 2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency. Annals of the rheumatic diseases. 2007;66(9):1210–5.CrossRef

24.

Kawasaki ES. Sample preparation from blood, cells, and other fluids. PCR protocols: a guide to methods and applications. 1990;1.

25.

Dorman JS, Bunker CH. HLA-DQ locus of the human leukocyte antigen complex and type 1 diabetes mellitus: a HuGE review. Epidemiol Rev. 2000;22(2):218–27.CrossRef

26.

Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39(7):857–64.CrossRef

27.

Plagnol V, Howson JM, Smyth DJ, Walker N, Hafler JP, Wallace C, et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet. 2011;7(8):e1002216.CrossRef

28.

Walter MA, Chambers CA, Zimmerman B, Cox DW. A multigene deletion in the immunoglobulin heavy chain region in a highly atopic individual. Hum Genet. 1990;85(6):643–7.CrossRef

29.

Avnir Y, Watson CT, Glanville J, Peterson EC, Tallarico AS, Bennett AS, et al. IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Sci Rep. 2016;6(1):1–13.CrossRef

30.

Liu L, Lucas AH. IGH V3–23* 01 and its allele V3–23* 03 differ in their capacity to form the canonical human antibody combining site specific for the capsular polysaccharide of Haemophilus influenzae type b. Immunogenetics. 2003;55(5):336–8.CrossRef

31.

Chang C-J, Chen C-H, Chen B-M, Su Y-C, Chen Y-T, Hershfield MS, et al. A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. Nat Commun. 2017;8(1):1–7.CrossRef

32.

Tang S-J. The R-Operon: a model of repetitive DNA-organized transcriptional compartmentation of eukaryotic chromosomes for coordinated gene expression. Genes. 2016;7(4):16.CrossRef

33.

Choi NM, Feeney AJ. CTCF and ncRNA regulate the three-dimensional structure of antigen receptor loci to facilitate V (D) J recombination. Front Immunol. 2014;5:49.CrossRef

Title: Association of IGHM polymorphisms with susceptibility to type 1 diabetes
Authors: Zouidi Ferjeni
Fakhfakh Raouia
O. Abida
C. Penha-Gonçalves
H. Masmoudi
Publication date: 20-01-2022
Publisher: Springer US
Keyword: Type 1 Diabetes
Published in: Immunologic Research / Issue 3/2022
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-021-09252-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association of IGHM polymorphisms with susceptibility to type 1 diabetes

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Identification of nafamostat mesylate as a selective stimulator of NK cell IFN-γ production via metabolism-related compound library screening

PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy

An overview of the biological and multifunctional roles of IL-38 in different infectious diseases and COVID-19

Feasibility of identifying plasma donors with high measles neutralizing antibody concentrations for the use of producing a measles hyperimmune globulin for postexposure prophylaxis

Microarray profiling and functional analysis reveal the regulatory role of differentially expressed plasma circular RNAs in Hashimoto’s thyroiditis

Association of the MARCO polymorphism rs6761637 with hepatocellular carcinoma susceptibility and clinical characteristics